Eli Lilly & CO 8-K filings

Eli Lilly and Company announced robust second-quarter 2026 financial results, driven by Mounjaro and Zepbound, and raised its full-year revenue and non-GAAP EPS guidance.

Eli Lilly and Company has successfully completed a significant debt offering, raising approximately $8.94 billion to fund its operations and strategic initiatives.

Eli Lilly and Company held its 2026 Annual Meeting of Shareholders on May 4, 2026, where key director elections, executive compensation, auditor ratification, and several governance proposals were put to a vote.

Eli Lilly reported a 56% revenue increase in Q1 2026, driven by strong volume growth, and raised its full-year financial guidance.

Eli Lilly reports robust fourth-quarter 2025 financial results with 43% revenue growth and strong 2026 guidance, driven by key obesity and diabetes medicines.

Eli Lilly and Company announced the election of Dr. Carolyn R. Bertozzi, a distinguished Stanford professor and Nobel laureate, to its Board of Directors, effective December 8, 2025.

Eli Lilly and Company reported a robust 54% increase in third-quarter 2025 revenue to $17.60 billion, driven by strong demand for Mounjaro and Zepbound, and raised its full-year financial guidance.

Eli Lilly and Company successfully completed a multi-tranche debt offering, raising approximately $6.71 billion in net proceeds through the issuance of fixed and floating rate notes.

Eli Lilly and Company reported a 38% increase in second-quarter 2025 revenue to $15.56 billion, driven by strong sales of Zepbound and Mounjaro, leading to raised full-year guidance.

Eli Lilly held its annual shareholder meeting on May 5, 2025, with key votes on director elections, executive compensation, auditor ratification, and proposed amendments to the company's Articles of Incorporation.

Eli Lilly's Q1 2025 revenue surged 45% to $12.73 billion, fueled by the strong performance of Mounjaro and Zepbound, with pipeline advancements including positive Phase 3 results for orforglipron.

Eli Lilly and Company issues $6.5 billion in notes across six series with maturities ranging from 2028 to 2065.

Eli Lilly's Q4 2024 revenue surged 45% to $13.53 billion, fueled by volume growth from Mounjaro and Zepbound, with 2025 revenue guidance set between $58.0 billion and $61.0 billion.

Eli Lilly projects substantial revenue growth for 2025, driven by new product launches and increased demand for existing medications, while also updating its 2024 revenue expectations.

Eli Lilly and Company has announced the appointment of Jon Moeller to its board of directors and the transition of Karen Walker's role, effective December 2024.

Eli Lilly's Q3 2024 financial results show a 20% revenue increase, driven by strong volume growth from new products like Mounjaro and Zepbound, and a 42% increase excluding a prior year divestiture.

Eli Lilly and Company has announced the appointment of Lucas Montarce as its new executive vice president and chief financial officer, effective immediately.

Eli Lilly and Company announced the retirement of board member Marschall S. Runge, effective August 31, 2024.

Eli Lilly and Company has successfully issued $5 billion in debt securities through five different tranches with varying maturities and interest rates.

Eli Lilly reported a 36% increase in revenue for Q2 2024, driven by strong sales of Mounjaro, Zepbound, and Verzenio, and subsequently raised its full-year revenue guidance by $3 billion.

Eli Lilly and Company has announced the resignation of its CFO, Anat Ashkenazi, and the appointment of Gordon Brooks as interim CFO, effective July 15, 2024.

Eli Lilly and Company announced the resignation of its Chief Financial Officer, Anat Ashkenazi, effective July 2024, as she pursues opportunities outside the pharmaceutical industry.

Eli Lilly held its annual shareholder meeting on May 6, 2024, where directors were elected, executive compensation was approved, and several shareholder proposals were voted on.

Eli Lilly reported a 26% increase in revenue for the first quarter of 2024, driven by strong sales of Mounjaro and Zepbound, and raised its full-year revenue guidance by $2 billion.

Eli Lilly and Company has successfully priced and issued $6.5 billion in debt securities across five different tranches with varying maturities and interest rates.

Eli Lilly announced a 28% increase in revenue for Q4 2023, driven by new products like Mounjaro and Zepbound, and provided an optimistic outlook for 2024.